335 related articles for article (PubMed ID: 30390769)
1. Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer.
Freimund AE; Beach JA; Christie EL; Bowtell DDL
Hematol Oncol Clin North Am; 2018 Dec; 32(6):983-996. PubMed ID: 30390769
[TBL] [Abstract][Full Text] [Related]
2. Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma.
Chen X; Zhang J; Zhang Z; Li H; Cheng W; Liu J
Hum Pathol; 2013 Nov; 44(11):2373-84. PubMed ID: 23850493
[TBL] [Abstract][Full Text] [Related]
3. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
[TBL] [Abstract][Full Text] [Related]
4. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
[TBL] [Abstract][Full Text] [Related]
6. PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.
Tang M; O'Connell RL; Amant F; Beale P; McNally O; Sjoquist KM; Grant P; Davis A; Sykes P; Mileshkin L; Moujaber T; Kennedy CJ; deFazio A; Tan K; Antill Y; Goh J; Bonaventura T; Scurry J; Friedlander M
Gynecol Oncol; 2019 Sep; 154(3):531-538. PubMed ID: 31227223
[TBL] [Abstract][Full Text] [Related]
7. ZNF671 DNA methylation as a molecular predictor for the early recurrence of serous ovarian cancer.
Mase S; Shinjo K; Totani H; Katsushima K; Arakawa A; Takahashi S; Lai HC; Lin RI; Chan MWY; Sugiura-Ogasawara M; Kondo Y
Cancer Sci; 2019 Mar; 110(3):1105-1116. PubMed ID: 30633424
[TBL] [Abstract][Full Text] [Related]
8. Unveiling the epigenomic mechanisms of acquired platinum-resistance in high-grade serous ovarian cancer.
Silva R; Glennon K; Metoudi M; Moran B; Salta S; Slattery K; Treacy A; Martin T; Shaw J; Doran P; Lynch L; Jeronimo C; Perry AS; Brennan DJ
Int J Cancer; 2023 Jul; 153(1):120-132. PubMed ID: 36883413
[TBL] [Abstract][Full Text] [Related]
9. Exploring the Clinical Impact of Predictive Biomarkers in Serous Ovarian Carcinomas.
Le Page C; Chung J; Rahimi K; Köbel M; Provencher D; Mes-Masson AM
Curr Drug Targets; 2020; 21(10):974-995. PubMed ID: 31622218
[TBL] [Abstract][Full Text] [Related]
10. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ
Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
[TBL] [Abstract][Full Text] [Related]
11. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
[TBL] [Abstract][Full Text] [Related]
12. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
[TBL] [Abstract][Full Text] [Related]
13. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance.
Salani R; Kurman RJ; Giuntoli R; Gardner G; Bristow R; Wang TL; Shih IM
Int J Gynecol Cancer; 2008; 18(3):487-91. PubMed ID: 17692090
[TBL] [Abstract][Full Text] [Related]
14. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
15. [Factors of resistance of ovarian cancer to combined chemotherapy with the use of platinum derivatives].
Bliumenberg AG; Gorbacheva LB; Gorbunova VA; Kozachenko VP; Lankin VZ
Biull Eksp Biol Med; 1996 Dec; 122(12):651-4. PubMed ID: 9280465
[No Abstract] [Full Text] [Related]
16. Platelet-Derived Growth Factor D Is a Prognostic Biomarker and Is Associated With Platinum Resistance in Epithelial Ovarian Cancer.
Zhang M; Liu T; Xia B; Yang C; Hou S; Xie W; Lou G
Int J Gynecol Cancer; 2018 Feb; 28(2):323-331. PubMed ID: 29240605
[TBL] [Abstract][Full Text] [Related]
17. Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer.
Huang D; Chowdhury S; Wang H; Savage SR; Ivey RG; Kennedy JJ; Whiteaker JR; Lin C; Hou X; Oberg AL; Larson MC; Eskandari N; Delisi DA; Gentile S; Huntoon CJ; Voytovich UJ; Shire ZJ; Yu Q; Gygi SP; Hoofnagle AN; Herbert ZT; Lorentzen TD; Calinawan A; Karnitz LM; Weroha SJ; Kaufmann SH; Zhang B; Wang P; Birrer MJ; Paulovich AG
Cell Rep Med; 2021 Dec; 2(12):100471. PubMed ID: 35028612
[TBL] [Abstract][Full Text] [Related]
18. Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
Fang L; Wang H; Li P
Invest New Drugs; 2018 Apr; 36(2):187-194. PubMed ID: 29082457
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
20. Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatin.
Soyama H; Miyamoto M; Takano M; Aoyama T; Matsuura H; Sakamoto T; Takasaki K; Kuwahara M; Kato K; Yoshikawa T; Iwahashi H; Tsuda H; Furuya K
Med Oncol; 2017 Nov; 34(12):201. PubMed ID: 29168038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]